October Upside Ranks
Qualitative relative target-touch selections · Not calibrated probabilities
Dated prices · targets are price touches, not forecasts · exact ranks are editorial judgments.
Grade legend, dates & research limits
Completed editorial grades · assessed October 6. Business = demonstrated commercial traction. Catalyst = clarity and timing of the next important test, not success odds. Target path = how demanding this list’s target is. These grades use the same rubric for all selected names; they are not native financial-model grades or statistical probabilities.
A strong / direct · B supported but conditional · C speculative or major gaps · D exceptional leap / weak bridge. A strong catalyst can fail. A fivefold target can have a D path even in a top-ranked moonshot.
Exact grading benchmarks & evidence dates
Business
How far the business inflection is demonstrated today, not source completeness.
- A — Broad, realized commercial growth or earnings; not just a plan.
- B — Real but early, concentrated or mixed operating traction.
- C — Primarily clinical/development or capacity optionality; limited realized economics.
- D — Retained facts undermine the proposed business inflection.
Catalyst
Specificity, observability and timing of a thesis-changing test inside the original window, not its chance of success.
- A — A scheduled or explicitly windowed material readout, launch or commercial ramp; repeated hard operating tests may qualify.
- B — Concrete delivery, orders or earnings tests, but diffuse timing or less discrete thesis change.
- C — A real milestone with important acceptance/economics/timing gaps.
- D — No supported material in-window test.
Target path
Burden of reaching THIS tier target from the dated baseline; not an absolute odds estimate.
- A — Comparatively direct earnings/recognition bridge in retained evidence; still conditional.
- B — Recognizable bridge, but meaningful premium, execution or share-claim sensitivity.
- C — Speculative extension or binary rerating beyond established economics; small-base elasticity is not a forecast.
- D — Exceptional leap far beyond retained cases, with major scale/valuation/financing obstacles.
No bell curve, numeric weights, A+ grades, probability conversion or grade-based reranking. Same rubric for incumbents and additions; target-path grades vary by tier. A catalyst can fail. No synchronized chart grading because technical coverage is not comparable across all 19.
Assessment October 6 of retained evidence, not an October 6 source refresh. Baseline October 1; existing remaining touch window October 4, 2026 to exclusive October 1, 2027. Original source cutoff October 3; additions retrieved October 4; Bloom narrative retrieved October 5 UTC. Original publication dates remain attached to sources.
Original conservative research grades remain in each full story. Partial financial underwriting remains partial: completed qualitative grades do not certify current cash, target dilution, clinical efficacy or funded forecasts. No chart grade is invented from unmatched technical snapshots.
Targets use October 1, 2026 baseline quotes, which are not live prices. The price-touch window is October 4, 2026 to exclusive October 1, 2027, not the price at expiry. Exact ordinal differences are low-confidence editorial judgments; absolute likelihood may be low.
Original financial source cutoff: October 3, 2026, 07:14:12.687379 UTC. Biotech sources retrieved October 4 with original publication dates retained. Bloom’s power and policy narrative reviewed October 4 ET (sources retrieved October 5 UTC). Publication does not clear research or model limitations. No calibrated odds.
ABSI · Absci
2x Conviction · #95x Moonshots · #9Oct1 baseline: USD 10.75. Historical daily quote retrieved Oct4.
The investment story
Thesis
Upcoming hair-loss trial results could reprice Absci’s antibody platform; success is unproven and disappointing data could sharply hurt shares.
What could move the stock
Upcoming hair-loss trial results could reprice Absci’s antibody platform; success is unproven and disappointing data could sharply hurt shares.
Next catalyst
Interim results expected in the second half of 2026; full readout expected early 2027.
Major risk
Clinical failure and future funding needs could cause substantial losses; investment is not proof of efficacy.
Editorial grades · October 6 assessment
Same rubric for every selected company. Business is demonstrated traction; Catalyst is the timing and clarity of a test, not its chance of success. Target path changes with the target burden.
2x Conviction
Business · C
Clinical-platform upside is not yet supported by meaningful recurring sales or proven randomized efficacy.
Catalyst · A
Hair-loss interim data expected in second-half 2026 and full readout early 2027 can change the thesis sharply.
Target path · C
A meaningful clinical readout can reprice a small platform, but the direction and magnitude are unproven and no funded double case is supplied.
Strongest countercase
Clinical disappointment and future financing can cause severe losses; partner investment is not efficacy proof.
Confidence & coverage
Low for target touch and adjacent ordering; moderate for the descriptive assessment of retained facts. Partial financial underwriting; current cash and target-dependent dilution unresolved.
5x Moonshots
Business · C
Clinical-platform upside is not yet supported by meaningful recurring sales or proven randomized efficacy.
Catalyst · A
Hair-loss interim data expected in second-half 2026 and full readout early 2027 can change the thesis sharply.
Target path · D
A major clinical repricing is possible, but fivefold needs an exceptional data-and-valuation response; no efficacy odds or funded bridge exists.
Strongest countercase
Clinical disappointment and future financing can cause severe losses; partner investment is not efficacy proof.
Confidence & coverage
Low for target touch and adjacent ordering; moderate for the descriptive assessment of retained facts. Partial financial underwriting; current cash and target-dependent dilution unresolved.
Grade evidence & preserved research grades
Editorial reader v2 is separate from native financial certification. The original conservative evidence/path grades below have not been upgraded or overwritten.
2x Conviction original research grades
Evidence: not supplied; operating pathway: not supplied; feasibility: not supplied.
5x Moonshots original research grades
Evidence: not supplied; operating pathway: not supplied; feasibility: not supplied.
- ABSI-10Q
Published: 2026-08-11 · Retrieved: 2026-10-04T14:05:02.506538+00:00 - ABSI-facts
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:05:02.506844+00:00 - ABSI-release
Published: 2026-08-11 · Retrieved: 2026-10-04T14:04:38.239177+00:00 - ABSI-sept24
Published: 2026-09-24 · Retrieved: 2026-10-04T14:07:32.476575+00:00 - ABSI-submissions
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:04:38.146936+00:00
Detailed research, financial evidence & sources
Business
Clinical-stage generative antibody platform with near-zero recognized partner revenue.
Financial quality
H1 partner revenue $0.533m vs $1.772m; no partner had clinical/commercial IP license as of Aug11. Large TAM is not booked sales. June blinded aggregate tolerability/PK is not randomized efficacy confirmation.
Claims and dilution
June $100m gross offering generated $93.6m net, already in June30 liquidity; $40m Lilly equity is included, not additional partner sales/cash. H1 ATM 3.662246m shares and $12.5m net already issued/received. Options23.140411m weighted strike$3.29, RSUs4.504668m; future strike-specific effects unknown; gross option share bound cannot be coupled to assumed full proceeds at weighted strike without sensitivity.
Guide / interpretation
Management operating-plan runway into second half2028 as of Aug11; conditional spending forecast, not committed future cash.
Countercase
Dated June liquidity and Aug11 conditional operating-plan runway support testing; actual Oct4 cash and target funding unknown. Randomized exploratory interim expected2H26/full early2027 can reprice, but Lilly investment is not efficacy validation and is already included.
Concrete catalysts — not efficacy promises
- HEADLINE hair-loss interim proof-of-concept expected 2H26; full26-week readout early2027.
- IMPORTANT Sept24 supersedes Aug11 endometriosis Q4 2026 start: STORYLINE initiation now anticipated mid2027, subject to regulatory clearance, protocol finalization and HEADLINE-informed dose selection. Planned~150 participants,~10+ countries. No substantiated endometriosis proof-of-concept inside12mo.
Dated reported financial evidence
US GAAP unaudited consolidated; flows 2026-01-01 through2026-06-30 inclusive; stocks June30 unless dated share cover. Units: reported USD millions unless a share count, ratio or date is explicitly named. These are not October 4 bank balances.
- cash
- 107.865
- securities
- 93.277
- liquid
- 201.142
- restricted
- 1.054
- debt
- 0.15
- debt and finance lease
- Unknown (null)
- op leases
- 3.679
- revenue
- 0.533
- operating income
- -65.004
- net income
- -62.809
- ocf
- -53.871
- capex
- 0.031
- sbc ocf
- 9.621
- sbc expense
- 9.625
- shares
- 171,614,010
- share date
- 2026-07-31
- weighted
- 155,217,585
- rsus
- 4,504,668
- options
- 23,140,411
Target burdens — static sensitivities, not forward fair value
Static reverse burden not forward fairvalue/funded hitcase; unknown actual current claims/cash not replaced by these dated balances.
1.35× baseline · USD 14.513
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 171.614
- datedLiquidityUSDm
- 201.142
- datedDebtUSDm
- 0.15
- requiredCommonEquityUSDm
- 2,490.548
- staticEVUSDm
- 2,289.556
2× baseline · USD 21.5
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 171.614
- datedLiquidityUSDm
- 201.142
- datedDebtUSDm
- 0.15
- requiredCommonEquityUSDm
- 3,689.701
- staticEVUSDm
- 3,488.709
5× baseline · USD 53.75
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 171.614
- datedLiquidityUSDm
- 201.142
- datedDebtUSDm
- 0.15
- requiredCommonEquityUSDm
- 9,224.253
- staticEVUSDm
- 9,023.261
Target-specific terminal shares: Unknown (null). Target-specific terminal cash: Unknown (null).
Discovery chart context
leadership · QQQ-relative discovery only, separate from AI100 runtime SPY scoring. Retained Oct1/Oct2 observations retrieved Oct4; no numerical rank against all incumbents.
- return20d
- 0.222
- return60d
- -0.063
- return120d
- 2.525
- distanceHigh
- -0.108
- range20d
- 0.447
- relative60d
- -0.09
Risks and unresolved inputs
- Oct4 actual liquid balances
- Target-dependent dilution and future issuance
- Market expectations baseline
- Exact forecast peak cash
2x Conviction strongest countercase
NBIS has real Reflection/Cohere deals and delivered Microsoft tranches; ABSI60-interval return is -6.28%, QQQ-relative -8.98 percentage points, and no randomized efficacy result has yet been established. Double requires $21.50 and ~$3.690bn dated-common equity, with future dilution unresolved.
5x Moonshots strongest countercase
SEI has actual commissioning/raised-guide receipts. ABSI $53.75 target needs ~$9.224bn on dated common shares alone; future claims could raise the burden. A 5x move would require exceptionally favorable data/platform extrapolation or speculative premium, none evidenced as achieved; trial disappointment can sharply reverse the stock.
- ABSI-10Q
Published: 2026-08-11 · Retrieved: 2026-10-04T14:05:02.506538+00:00 - ABSI-facts
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:05:02.506844+00:00 - ABSI-release
Published: 2026-08-11 · Retrieved: 2026-10-04T14:04:38.239177+00:00 - ABSI-sept24
Published: 2026-09-24 · Retrieved: 2026-10-04T14:07:32.476575+00:00 - ABSI-submissions
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:04:38.146936+00:00